Drug Profile

Research programme: proto oncogene proteins c-akt inhibitors - Astex/Institute of Cancer Research/Cancer Research Technology

Alternative Names: AT 11854; AT 7867; CCT 128930; CCT 129254; CCT077373; CCT077933

Latest Information Update: 04 Nov 2017

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Astex Therapeutics; Cancer Research UK; The Institute of Cancer Research
Developer Astex Pharmaceuticals; Cancer Research UK; The Institute of Cancer Research
Class Benzamides; Piperidines; Pyrazoles; Pyrimidines; Small molecules
Mechanism of Action 70 kDa ribosomal protein S6 kinase inhibitors; Proto-oncogene protein c-akt inhibitors; Rho-associated kinase inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

04 Nov 2017 No recent reports of development identified for preclinical development in Cancer in United Kingdom (PO)
11 Oct 2013 Astex Pharmaceuticals has been acquired by Otsuka Pharmaceutical
20 Jul 2011 Astex Therapeutics has been acquired by SuperGen

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com